The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $35.23

Today's change+0.22 +0.63%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $35.23

Today's change+0.22 +0.63%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Bio-Reference Laboratories Inc crosses above 20-day moving average

Bio-Reference Laboratories Inc closed up Friday by (U.S.)$0.22 or 0.63% to (U.S.)$35.23 and crossing above its 20-day moving average. Over the last five days, shares have gained 1.88% and are currently 4.14% off of the 52-week high. Shares have outperformed the S&P 500 by 19.22% during the last year.

Key company metrics

  • Open(U.S.) $35.14
  • Previous close(U.S.) $35.01
  • High(U.S.) $35.56
  • Low(U.S.) $34.81
  • Bid / Ask-- / --
  • YTD % change+9.65%
  • Volume100,395
  • Average volume (10-day)147,245
  • Average volume (1-month)137,321
  • Average volume (3-month)237,460
  • 52-week range(U.S.) $24.19 to (U.S.) $36.75
  • Beta0.74
  • Trailing P/E19.46×
  • P/E 1 year forward17.56×
  • Forward PEG1.03×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.81
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.87%

Based on its net profit margin of 5.87%, Bio-Reference Laboratories Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJan 31, 201501/31/2015Oct 31, 201410/31/2014Jul 31, 201407/31/2014Apr 30, 201404/30/2014
Revenue209228222201
Total other revenue--------
Total revenue209228222201
Gross profit9010710289
Total cost of revenue119121120113
Total operating expense197197194182
Selling / general / administrative76757368
Research & development--------
Depreciation / amortization2212
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income12312819
Interest income (expense), net non-operating-1-1-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax12302718
Income after tax7181510
Income tax, total512128
Net income7181510
Total adjustments to net income--------
Net income before extra. items7181510
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items7181510
Inc. avail. to common incl. extra. items7181510
Diluted net income7181510
Dilution adjustment--------
Diluted weighted average shares28282828
Diluted EPS excluding extraordinary itemsvalue per share0.240.660.550.37
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.240.660.550.37